RO7268489 for Progressive Multiple Sclerosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 360 (estimated)
- Sponsor
- Hoffmann-La Roche · Industry
This trial is looking for adults with progressive multiple sclerosis who are currently taking ocrelizumab. Participants may receive an additional treatment called RO7268489 and will be monitored for its effects.
You may be able to join if
- I have progressive multiple sclerosis.
- I have an EDSS score between 3.0 and 6.0.
You may not be able to join if
- I have had a relapse of MS in the past 6 months.
- I don't have a usable vein for access.
- I have a history of drug or alcohol abuse in the last 5 years.
- I cannot have an MRI.
- I cannot take the required pre-medications for ocrelizumab.
- I have had IV immunoglobulin or plasmapheresis in the last 12 weeks.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an open-label (OL) extension may allow eligible participants to receive open-label RO7268489.
Loading trial locations…
Reference Study ID Number: BP46016 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT